Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022
Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
- Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
- Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
- OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
- For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com